186692-45-5

Usage

Uses

Used in Pharmaceutical Research:
(S)-ROSCOVITINE is used as a research tool for investigating the potential therapeutic applications of CDK inhibitors in cancer and other diseases. Its ability to inhibit specific CDKs makes it a promising candidate for the development of targeted cancer therapies.
Used in Anticancer Applications:
(S)-ROSCOVITINE is used as an anti-cancer agent in preclinical studies, demonstrating promise in targeting the cell growth and division processes that are often dysregulated in cancer cells. By inhibiting CDKs, it may help to halt the progression of the disease.
Used in Neurodegenerative Disease Research:
(S)-ROSCOVITINE is used as a potential therapeutic agent for the treatment of neurodegenerative diseases, due to its neuroprotective and anti-inflammatory effects. These properties suggest that it may help to protect neurons and reduce inflammation, which are common features of neurodegenerative conditions.
Used in Inflammatory Disease Research:
Similarly, (S)-ROSCOVITINE is used as a potential therapeutic agent for the treatment of inflammatory diseases, leveraging its anti-inflammatory effects to potentially alleviate symptoms and modify the disease course.

Upstream product

• 5451-40-1 2,6 dichloropurine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 5856-63-3 (2R)-2-aminobutan-1-ol 
• 186692-41-1 2-chloro-6-phenylmethylamino-9-iso-propylpurine 
• 5856-62-2 (S)-2-aminobutan-1-ol 
• 39639-47-9 N⁶-benzyl-2-chloroadenine 
• 96-20-8 2-aminobutanol 
• 100-46-9 benzylamine 
• 1651-29-2 6-chloro-2-fluoropurine 
• 482615-52-1 N-benzyl-2-fluoro-9-isopropyl-purin-6-amine 
• 3800-23-5 N-benzyl-2-fluoro-9H-purin-6-amine 

Downstream Products

• 1428319-98-5 (2R)-2-[[6-benzylamino-9-isopropyl-9H-purin-2-yl]amino]butyl 4-(nitrooxy)-butanoate 

Relevant academic research and scientific papers

Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer

The cyclin-dependent kinase inhibitor (R)-2-(6-benzylamino-9-isopropyl-9H-purin-2-ylamino)butan-1-ol (roscovitine, 1a), as well as its (S)-enantiomer 1b, were synthesised. The chemical structure and absolute configuration of both enantiomers was confirmed by X-ray crystallography. Furthermore, high enantiomeric excess (>98%) was demonstrated by chiral chromatography of 1a and 1b, as well as NMR analysis of the diastereomeric Mosher's ester derivatives 2a and 2b.

Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound αSβR-21 inhibits CDK2/cyclin E with IC50 = 30 nM, CDK7-cyclin H with IC50 = 1.3 μM, and CDK9-cyclinT with IC50 = 0.11 μM; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI50 = 0.7 μM; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts.

The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe M?ssbauer), theoretical, and biological activity studies

The first FeIII complexes 1-6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(Ln)Cl3]·nH2O (n=0 for 1, 1 for 2, 2 for 3-6; L1-L6=C2- and phenyl-substituted CDK inhibitors derived from 6-benzylamino-9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, 57Fe Mo?ssbauer, 1H and 13C NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S=5/2) FeIII complexes with an admixture of an S=3/2 spin state originating probably from five-coordinated FeIII ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82μeff/μB) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the FeIII ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4-23μM) and inhibition activity (IC50: 0.02-0.09μM) results have been achieved in the case of complexes 2-4, and complexes 3, 4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L1, L4 and L5, is also described.

Practical synthesis of roscovitine and CR8

Roscovitine and CR8 are potent inhibitors of cyclin-dependent kinases. A scalable synthesis of both inhibitors is described. In the case of CR8, the biarylmethylamine moiety was obtained as a stable and high-purity salt.

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1

Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC50: 220 nM), CDK5/p25 (IC50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1δ provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-β in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.

Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds

Cyclin-dependent kinases (cdk) have recently raised considerable interest in view of their essential role in the regulation of the cell division cycle. The structure-activity relationships of edk inhibition showed that the 1, 3, and 7 positions of the purine ring must remain free, probably for a direct interaction, in which it behaves as a hydrogen bond acceptor. Olomoucine (6-(benzylamino)-2-[(2-hydroxyethyl)amino]-9-methylpurine, OC), roscovitine (6-(benzylamino)2(R)-[[1-(hydroxymethyl)propyl]amino]-9- isopropylpurine), and other N6,2,9-trisubstituted adenines were found to exert a strong inhibitory effect on the p34(cdc2)/cyclin B kinase. Removal or change of the side chain at position 2 or the hydrophobic group at position 9 dramatically decreased the inhibitory activity of olomoucine or roscovitine. Inhibition of cdk with OC and related compounds clearly arrests cell proliferation of many tumor cell lines at G1/S and G2/M transitions and also triggers apoptosis in the target tumor cells in vitro and in vivo. Thus, from a pharmacological point of view, OC may represent a model compound for a new class of antimitotic and antitumor drugs.